@ShaneyWright There are some ongoing trials using immune modulating drugs, including the one we are doing. I agree we should focus more on autoimmunity of long COVID. https://t.co/F0Ivz8vByX
NIH funding is a major driver of biomedical research, but they are extremely risk-averse. As a result, there has been almost no NIH funding for newfound conditions such as POTS, while millions of Americans are suffering from it. This needs to change immediately!
imagine if scientific funding worked more like VC funding - capital for young scientists pursuing high-risk/high-upside hypotheses. instead, the NIH does the opposite - the majority of funding goes to already well-funded 66+ year-old tenured professors pursuing incremental ideas
imagine if scientific funding worked more like VC funding - capital for young scientists pursuing high-risk/high-upside hypotheses. instead, the NIH does the opposite - the majority of funding goes to already well-funded 66+ year-old tenured professors pursuing incremental ideas